SGI
AGRX

Summit Global Investments’s Agile Therapeutics AGRX Stock Holding History

Summit Global Investments’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-63
Closed -$121K – 646
2021
Q3 		$121K Buy
63
+8
+15% +$18.1K 0.01% 457
2021
Q2 		$146K Buy
+55
New +$181K 0.01% 547

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Global Investments's AGRX Position: Q4 2021 in Review

Summit Global Investments sold out of Agile Therapeutics (AGRX) in Q4 2021, closing a stake of 63 shares — an estimated $121K sold.

Summit Global Investments first reported a position in AGRX in Q2 2021 and held it in 2 quarters. The position peaked at $146K in Q2 2021. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2021.

  • Summit Global Investments reported no remaining Agile Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Summit Global Investments sold 63 Agile Therapeutics shares in Q4 2021, an estimated $121K.
  • Summit Global Investments first reported a position in Agile Therapeutics in Q2 2021 and held it in 2 quarters.
  • Summit Global Investments's Agile Therapeutics position peaked at $146K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2021.

Based on Summit Global Investments's 13F filing for Q4 2021, filed 14 Feb 2022.